Supplementary Figure S1 from Novel Genomic Risk Stratification Model for Primary Gastrointestinal Stromal Tumors (GIST) in the Imatinib and Adjuvant Therapy Era

Supplementary Figure 1. Traditional risk stratification in primary gastric and small bowel GIST. Primary gastric (A-C) and small bowel (D-F) GISTs localized at diagnosis without prior neoadjuvant treatment are risk stratified into low, moderate, and high risk groups based on site, tumor size and mitotic rate using the Miettinen (also includes very low risk) (A, D), Fletcher (B, E) and Joensuu (C, F) risk stratification schemes (Miettinen 2006, Fletcher 2002, Joensuu 2008). Recurrence-free survival for patients in each of these risk groups is represented by Kaplan-Meier curves (global log-rank P) for all primary localized cases.